Țară: Canada
Limbă: engleză
Sursă: Health Canada
LANSOPRAZOLE
SUN PHARMA CANADA INC
A02BC03
LANSOPRAZOLE
30MG
CAPSULE (DELAYED RELEASE)
LANSOPRAZOLE 30MG
ORAL
100
Prescription
PROTON-PUMP INHIBITORS
Active ingredient group (AIG) number: 0127666004; AHFS:
APPROVED
2020-02-04
_Taro-Lansoprazole _ _Page 1 of 83_ PRODUCT MONOGRAPH PR TARO-LANSOPRAZOLE Lansoprazole Delayed-Release Capsules USP 15 mg and 30 mg H + , K + – ATPase Inhibitor Sun Pharma Canada Inc. 126 East Drive Brampton, Ontario L6T 1C1 Date of Revision: SEP 01, 2023 Submission Control No: 278144 _Taro-Lansoprazole _ _Page 2 of 83_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................................................ 3 SUMMARY PRODUCT INFORMATION .............................................................................................................. 3 INDICATIONS AND CLINICAL USE .................................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................................ 5 WARNINGS AND PRECAUTIONS ....................................................................................................................... 5 ADVERSE REACTIONS ....................................................................................................................................... 12 DRUG INTERACTIONS ....................................................................................................................................... 21 DOSAGE AND ADMINISTRATION.................................................................................................................... 23 OVERDOSAGE ..................................................................................................................................................... 26 ACTION AND CLINICAL PHARMACOLOGY .................................................................................................. 26 STORAGE AND STABILITY ............................................................................................................................... 31 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................. Citiți documentul complet